Dramin B6

Quick links to important sections

Dramin B6

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dramin B6

What is Dramin B6?

Dramin B6 is a combination pharmaceutical product primarily used to address symptoms associated with motion sickness, nausea, and vomiting. It consists of two active ingredients that work through different mechanisms to provide relief from gastrointestinal distress and equilibrium-related discomfort.

Composition and Active Ingredients

The formulation typically contains the following components:

  • Dimenhydrinate: An antihistamine that acts as the primary agent for managing nausea and dizziness. It functions by interfering with certain signals in the brain and inner ear that trigger the vomiting reflex and feelings of vertigo.
  • Pyridoxine Hydrochloride (Vitamin B6): A water-soluble vitamin that plays a supportive role in metabolic processes. In this combination, it is included to assist in the mitigation of nausea, particularly in contexts where vitamin deficiencies or metabolic factors may contribute to symptoms.

Therapeutic Purpose

The medication is designed to assist individuals experiencing nausea and vomiting resulting from various causes, such as sea travel, air travel, or other forms of motion. By combining an antihistamine with Vitamin B6, the product aims to address both the neurological triggers of nausea and the physiological needs of the body during episodes of digestive upset.

What side effects are possible with Dramin B6?

Possible Side Effects and Safety Information

The officially documented safety profile for this fixed-dose combination, which contains Dimenhydrinate and Pyridoxine, outlines adverse reactions categorized primarily by frequency and the physiological systems affected. Regulatory documents consistently classify drowsiness and sedation as the most frequent and expected adverse reactions, alongside dizziness and anticholinergic effects like dry mouth.

Adverse Reaction System-Organ Classes

The documented side effects span several system-organ classes, reflecting the Dimenhydrinate component's properties:

  • Nervous System: Sedation, Dizziness, Headache.
  • Gastrointestinal: Dry mouth, Epigastric distress.
  • Eye Disorders: Blurred vision.
  • Renal and Urinary: Urinary retention or difficulty with urination.
  • Cardiac: Tachycardia (increased heart rate) or palpitations.

Serious and Population-Specific Safety Notes

Official labeling describes that certain serious adverse reactions are possible, often in cases of massive overdosage or specific patient sensitivity, including convulsions and cardiac arrhythmias. Furthermore, time-related safety notes indicate that tolerance to the sedative effects may develop after a few days of treatment.

Safety statements are explicitly provided for specific populations. Pediatric patients may experience a paradoxical central nervous system stimulation (such as excitement or restlessness) rather than the anticipated sedation. Older adults are more susceptible to adverse effects, including confusion and increased drowsiness.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Dramin B6, due to the Dimenhydrinate component, presents as a severe exaggeration of its effects. Regulatory documentation mandates that immediate emergency medical attention must be sought for any suspected overdose.

Officially documented clinical signs include Central Nervous System (CNS) effects that can range from profound drowsiness and stupor to CNS excitation, manifesting as hallucinations, agitation, and seizures. Signs of Anticholinergic Syndrome are often present, such as dilated pupils (mydriasis), flushed face, and dry mouth.

Severe outcomes documented in official sources include cardiovascular collapse, serious heart rhythm disturbances, and hyperpyrexia (elevated body temperature). The pediatric population is noted to be particularly susceptible to severe CNS excitation. Treatment is formally described as symptomatic and supportive; no specific antidote is known, though certain agents may be used in a controlled hospital setting for specific symptoms.

Immediate emergency services must be called if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Dramin B6

What Dramin B6 Treats: Main Uses and Benefits

Dramin B6 is utilized for the symptomatic relief of discomforts related to the balance system and other causes of gastric upset. The medication is commonly used to help manage symptoms such as nausea, vomiting, and dizziness.

Clinical Applications

This medicine is indicated to provide relief in several key clinical scenarios. These include the prevention and treatment of motion sickness, the management of certain types of vertigo, and the alleviation of nausea and vomiting associated with pregnancy (NVP). The essential benefit for the patient is the ability to support comfort and functional ability during these temporary symptomatic episodes.


Quick Facts: Therapeutic Uses

Dramin B6 is used for symptomatic relief to mitigate the distress caused by symptoms like spinning sensations, vomiting, and stomach upset related to motion sickness and pregnancy.

Eligibility and Restrictions for Use

Official Eligibility Profile

Regulatory documentation defines eligibility for Dramin B6 (dimenhydrinate/pyridoxine) based on age, physiological status, and underlying health conditions, primarily due to the effects of the dimenhydrinate component.

Eligibility Status Population/Condition
Contraindicated Neonates and children younger than 2 years of age.
Individuals with known hypersensitivity to dimenhydrinate or its components.
Conditional/Restricted Pregnant women: Use is only recommended if clearly needed and with physician consultation.
Nursing mothers: Drug is excreted in breast milk; a decision must be made to discontinue nursing or discontinue the drug.
Patients with conditions such as glaucoma, enlarged prostate, bronchial asthma, or cardiovascular disease require physician consultation before use.

Age Restrictions

The medicine is generally contraindicated for children under two years of age. Conditional use is permitted for older children (2–5 years) but is subject to specific dosing and should not be repeated except on the advice of a healthcare provider. Use in older adults (65 and over) requires caution due to an increased risk of specific side effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dramin B6, a combination of Dimenhydrinate (an H1 antihistamine with anticholinergic properties) and Pyridoxine Hydrochloride (Vitamin B6), has officially documented interactions primarily related to its antihistamine component's effects on the central nervous system (CNS) and its metabolic profile.

Contraindicated Combinations and Major Restrictions

The co-administration of Dimenhydrinate with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated in regulatory documents, including for up to 14 days after stopping an MAOI. This restriction is due to the potential for prolonged and intensified anticholinergic and CNS effects.

Pharmacodynamic and Metabolic Interactions

The most common documented interaction is additive CNS depression. This occurs with co-administration of alcohol, opioids, sedatives, and other CNS depressants, leading to increased drowsiness. Similarly, use with other Anticholinergic Agents (such as tricyclic antidepressants) results in additive anticholinergic effects.

In a pharmacokinetic context, the Dimenhydrinate component is documented as an inhibitor of the CYP2D6 enzyme. This interaction may increase the systemic exposure of co-administered medicines that are metabolized by this pathway, such as Metoprolol and Venlafaxine.

Specific Component and Procedural Constraints

  • Pyridoxine can reduce the therapeutic effect of Levodopa unless a dopa decarboxylase inhibitor is simultaneously given.
  • Dimenhydrinate can mask the warning symptoms of ototoxicity caused by agents like aminoglycoside antibiotics.
  • Timing rules mandate that the drug must be discontinued before a Secretin stimulation test to prevent a false procedural result.

Mechanism of Action

Mechanism of Action: Pharmacodynamics

Central Receptor Antagonism

The primary mechanism is mediated by Dimenhydrinate, which acts as a non-selective antagonist at central Histamine H1 and Muscarinic cholinergic receptors. These targets are highly concentrated within the vestibular nuclei and associated brainstem structures. By competitively blocking these receptor sites, the drug intercepts afferent neural signals originating from the peripheral balance organs, resulting in decreased neuronal excitability within the central vestibular system.

Pathway Modulation and Synergy

This central antagonism alters molecular signal transduction at the Chemoreceptor Trigger Zone (CTZ), lowering the sensitivity of the CTZ to circulating emetic stimuli and contributing to an increased activation threshold of the vomiting center. The secondary component, Pyridoxine (Vitamin B6), acts as an essential enzymatic cofactor for the synthesis and metabolism of central neurotransmitters, particularly GABA. This biochemical support modulates neurotransmitter systems, influencing neuronal excitability within pathways linked to efferent emetic signaling.

Dosage and Administration Information

How to Use Dramin B6

Dramin B6 is an antiemetic and antihistamine medication that, in its standard formulation, is administered via the oral route as a tablet. The proper administration of the medicine is defined by specific dose ranges, frequency, and timing constraints for its primary active component, Dimenhydrinate.


Official Administration Guidelines

Feature Guideline
Route of administration Oral route (tablet form).
Dosing schedule (Adults ge 12 years) A single dose is 50 mg to 100 mg. The total dose must not exceed 400 mg within a 24-hour period.
Timing in relation to meals May be administered with or without food.
Special procedural conditions For preventative use, the initial dose must be administered 30 minutes to 1 hour prior to the start of motion or activity.

Population-Specific Dosing

The usage instructions include specific dose adjustments for younger age groups:

  • Children 6 to under 12 years: 25 mg to 50 mg every 6 to 8 hours.
  • Children 2 to under 6 years: 12.5 mg to 25 mg every 6 to 8 hours.

Use Protocol

The official instructions establish a precise framework for administration, mandating specific intervals for repetition and setting a strict prophylactic timing rule to standardize the medicine’s use pattern. Dosing may be repeated in 4 to 6-hour intervals as needed, but this frequency is always subject to the maximum daily limit.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dramin B6

Evidence for Use in Motion Sickness

The primary body of research evidence available for motion sickness is based on studies of Dimenhydrinate, the antihistamine component. Studies conducted have mainly been short-term Randomized Controlled Trials (RCTs) and systematic reviews. This research was applied in studies examining patient-reported experiences and outcomes related to systemic or functional imbalance, such as nausea severity, vomiting frequency, and dizziness during exposure to actual or simulated motion.

Trials and systematic reviews examined the outcomes of the Dimenhydrinate component when compared to a placebo. Findings describe patterns observed in studies where the active component was associated with a change in measurements of patient-reported symptoms compared to the placebo group. The follow-up durations were limited, meaning that the long-term effects or sustained outcomes over repeated use are not well established.


Evidence for Use in Nausea and Vomiting of Pregnancy (NVP)

The research evidence available for NVP largely consists of studies on the Pyridoxine (Vitamin B6) component. The evidence for this use is often derived from Systematic Reviews, Meta-analyses, and large-scale RCTs. These studies were used in research exploring how symptoms change over time and assessed outcomes capturing phases of heightened symptom activity, such as tracking the intensity of nausea and the frequency of vomiting.

In studies conducted during periods of increased symptom activity, the use of Pyridoxine was observed to be associated with reported differences in symptom severity measurements compared to control groups. This evidence contributes to understanding symptom patterns in conditions associated with acute or disruptive episodes.

It is important to note that the most widely referenced clinical guidelines often use evidence from trials combining Pyridoxine with Doxylamine. Consequently, limited information is available specifically for the Dimenhydrinate and Pyridoxine combination in major authoritative sources for NVP.


What is Still Uncertain About the Dramin B6 Research

The evidence base highlights several areas where certainty remains low or research is still needed. A primary uncertainty is the availability of extensive comparative evidence for the Dimenhydrinate/Pyridoxine combination itself; much of the regulatory assessment relies on the established, individual action of its two components. Additionally, due to the acute, episodic nature of the conditions studied, follow-up durations were limited, and long-term effects are not fully established.

Key Studies & References

  1. Dimenhydrinate: MedlinePlus Drug Information (Monograph)
  2. Label: DIMENHYDRINATE injection, solution - DailyMed (Regulatory Monograph)

Frequently Asked Questions (FAQ)

Common questions about Dramin B6 (FAQ)

Q: How quickly does Dramin B6 start working for motion sickness?

A: According to official product information, when the medicine is used for prevention, the first dose is directed to be taken 30 minutes to 1 hour prior to the start of motion or activity. This timing is intended to ensure the active ingredients are present and working to block motion signals when needed.


Q: How long do the effects of Dramin B6 usually last?

A: The effects of a single dose of the active component are generally cited to last between 4 to 8 hours. Subsequent use is typically recommended at intervals of 4 to 6 hours, provided the maximum daily amount is not exceeded.


Q: Does Dramin B6 interact with common over-the-counter pain relievers?

A: The active ingredient can cause additive CNS depression (increased drowsiness) when combined with other substances that cause sleepiness. The product label warns that combining it with other CNS depressants, which may include certain pain relievers, may lead to increased drowsiness.


Q: Is Dramin B6 safe to use during pregnancy for morning sickness?

A: Use during pregnancy is recommended only if clearly needed and after consulting with a physician. Furthermore, the active component is known to be excreted into breast milk, and its use while nursing requires consideration.


Q: What is the difference between Dramin B6 and meclizine?

A: Both are H1-antihistamines used to treat motion sickness. A difference cited in regulatory documents is that Dimenhydrinate (the main part of Dramin B6) typically requires more frequent use, while Meclizine is often noted for having a longer duration of action.


Q: Can Dramin B6 be used for general stomach upset, not just motion sickness?

A: The medication is officially indicated for the prevention and relief of nausea, vomiting, and dizziness related to motion sickness and balance disturbances. Official indications focus on these specific symptoms and conditions.


Q: Can Dramin B6 cause rebound nausea when you stop taking it?

A: While not a common effect with proper short-term use, regulatory safety notes on the active ingredient mention that rebound nausea and dizziness have been reported. This effect is generally associated with the abrupt cessation following chronic heavy use.


Q: Does Dramin B6 have any impact on blood pressure?

A: Adverse event reports occasionally include minor effects on blood pressure, such as rare cases of mild increases or decreases. However, cardiovascular side effects are generally not listed as frequent adverse reactions in official labeling.


Q: Can Dramin B6 cause vision changes or blurred vision?

A: Yes, regulatory documents list blurred vision as one of the documented side effects. This is classified under Eye Disorders and is a known effect related to the drug's anticholinergic properties.


Q: Can older adults use Dramin B6 without increased risk?

A: Regulatory guidance advises caution for older adults (65 years and over) due to their increased susceptibility to adverse effects. These may include confusion and increased drowsiness. This is why special care and consultation are advised for older adults.


Q: Is Dramin B6 habit-forming if used frequently?

A: Official information regarding the active ingredient notes the potential for abuse due to its psychoactive effects at high doses. Regulatory documents also state that tolerance and dependence may develop with chronic heavy use.


Q: What should I do if I forget to take a dose of Dramin B6 before a trip?

A: If the medicine is taken on an as-needed basis, the dose is generally taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, regulatory guidance suggests that the missed dose should be skipped and the regular schedule continued.


Q: Does taking Dramin B6 require a prescription?

A: In many regions, the product containing Dimenhydrinate and Pyridoxine is generally available as an Over-The-Counter (OTC) drug. This means it can be purchased without a prescription for its indicated uses.


Q: Is it safe to take Dramin B6 with common cold or allergy medications?

A: Many cold and allergy medicines also contain antihistamines or other CNS depressants. The product information states that co-administration with these other CNS depressants may lead to additive drowsiness or intensified anticholinergic side effects.


Q: Why is Dramin B6 often recommended for sea travel?

A: The drug is indicated for the prevention and treatment of motion sickness. Sea travel is one of the most common causes of motion sickness, and the medication is used to block the motion signals from the inner ear that cause nausea and dizziness.


Q: Can Dramin B6 cause mild constipation or diarrhea?

A: The anticholinergic properties of the active ingredient are known to cause side effects such as dry mouth and may lead to issues like constipation or urinary retention due to their effect on involuntary smooth muscle function.


Q: Why do some people use Dramin B6 before amusement park rides?

A: The official indication covers motion sickness prevention caused by exposure to actual or simulated motion or activity. Since amusement park rides involve rapid and unusual movements, some people use the medicine preventatively for ride-induced motion sickness.


Q: Are there different strengths or formulations of Dramin B6 available?

A: Yes, official product information confirms that Dimenhydrinate-based products are commonly available in several forms for oral use, including standard tablets, chewable tablets, and syrup.


Q: What happens if you accidentally take two doses of Dramin B6 too close together?

A: Taking more than the recommended amount may lead to signs of overdosage, which can include pronounced drowsiness, confusion, hallucinations, or seizures. Contacting a Poison Control Center is strongly advised in case of suspected overdose.


Q: Can Dramin B6 be dissolved or crushed for easier swallowing?

A: Chewable tablet forms are specifically designed to be chewed or crushed completely before swallowing. Regular tablets are generally intended to be swallowed whole, but alternative forms are available.


Q: Does the effectiveness of Dramin B6 decrease with repeated use?

A: Regulatory safety notes specifically address the development of tolerance to the sedative effects of the drug after a few days of treatment.


Q: Does Dramin B6 have different effects on adults versus children?

A: Yes, regulatory warnings note a difference in effect. While adults typically experience sedation, pediatric patients may experience the opposite, which is a paradoxical central nervous system stimulation, such as excitement or restlessness.


Q: Can Dramin B6 affect the results of any lab tests?

A: Official labeling states that the drug must be discontinued before undergoing a Secretin stimulation test. This is because the medicine can interfere with the results, potentially leading to an inaccurate procedural outcome.


Q: Does Dramin B6 cause dependency if used for a long time?

A: Regulatory documents indicate the potential for tolerance and dependence to develop with chronic heavy use or misuse of the drug. This is noted as a safety concern related to long-term use patterns.

How should Dramin B6 be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Dramin B6 (Dimenhydrinate/Pyridoxine) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Condition Type Official Requirement
Temperature Range Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Environmental Protection Must be kept in a dry place and protected from moisture.
Container Integrity Store in the original container and keep it tightly closed.
Child Safety Keep out of the sight and reach of children.
Disposal Instructions Follow any specific disposal instructions on the label. Preferred methods are using drug take-back programs. If unavailable, mix with an undesirable substance (e.g., dirt) and seal before placing in household trash. Do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dramin B6 found in:

A-Z Index: